ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer’s Disease Conference
October 30, 2024 08:00 ET
|
ProMIS Neurosciences Inc.
Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target engagement Initiation of Phase 1b clinical trial in Alzheimer’s disease...
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
September 12, 2024 07:00 ET
|
ProMIS Neurosciences Inc.
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 12, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...
ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 05, 2024 07:00 ET
|
ProMIS Neurosciences Inc.
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Sept. 05, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...
ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights
August 08, 2024 07:00 ET
|
ProMIS Neurosciences Inc.
Reported positive topline data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease that met objectives for tolerability, safety and pharmacokinetics Secured...
ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology
August 06, 2024 07:00 ET
|
ProMIS Neurosciences Inc.
Body of work supports targeting misfolded proteins as a therapeutic strategy for ALS with the potential to translate across multiple neurodegenerative diseases CAMBRIDGE, Massachusetts and TORONTO,...
ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024
August 01, 2024 07:00 ET
|
ProMIS Neurosciences Inc.
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
July 30, 2024 08:30 ET
|
ProMIS Neurosciences Inc.
Preclinical data showed strong antibody responses with no measurable pro-inflammatory T cell responses against AßO and support novel approach for potential Alzheimer’s disease vaccine CAMBRIDGE,...
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
July 26, 2024 08:35 ET
|
ProMIS Neurosciences Inc.
Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospinal...
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
July 26, 2024 08:30 ET
|
ProMIS Neurosciences Inc.
$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the warrants subject to shareholder approval Fundraise supports development of...
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
May 14, 2024 16:01 ET
|
ProMIS Neurosciences Inc.
CAMBRIDGE, Massachusetts and TORONTO, Ontario, May 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and...